OncoEthix initiates OTX015 Phase I study in hematologic malignancies

Published on January 31, 2013 at 5:13 AM · No Comments

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient. OTX015 is a synthetic orally administered small molecule which targets BET bromodomain proteins 2/3/4, which are considered potential cancer targets because of their pivotal role in regulating the transcription of growth-promoting and cell cycle regulators, especially c-MYC. Phase I trials of OTX015 in healthy volunteers have already been completed.

The design of the Phase I trial will seek to determine the optimum dosing regimen for OTX015, and to provide further safety, pharmacokinetic and pharmacodynamic data. The study will be conducted in two parts: dose escalation, followed by expansion cohorts. In the first part, dose escalation and determination of the recommended dose will be performed independently in two parallel subsets of patients: patients with acute leukemia and patients with other hematologic malignancies. Once the optimum dosing regimen has been determined, the second part of the study will further assess safety, pharmacokinetics, pharmacodynamics and clinical activity in disease specific cohorts of at least 12 patients treated at the recommended dose. Study centers are now open at five reference sites in Europe [France, Italy and Switzerland] selected for investigators having extensive hematology and clinical pharmacology expertise.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post